'''Pyrovalerone''' ('''Centroton''', '''4-Methyl-β-keto-prolintane''', '''Thymergix''', '''O-2371''')<ref>US Patent 3314970</ref> is a [[psychoactive drug]] with [[stimulant]] [[therapeutic effect|effects]] via [[drug action|acting]] as a [[norepinephrine-dopamine reuptake inhibitor]] (NDRI), and is used for the [[clinic]]al [[therapy|treatment]] of [[chronic fatigue syndrome|chronic fatigue]] or [[lethargy]]<ref>{{Cite journal | last1 = Gardos | first1 = G. | last2 = Cole | first2 = J. O. | title = Evaluation of pyrovalerone in chronically fatigued volunteers | journal = Current Therapeutic Research, Clinical and Experimental | volume = 13 | issue = 10 | pages = 631–635 | year = 1971 | pmid = 4402508}}</ref> and as an [[anorectic]] or [[appetite suppressant]] for [[weight loss]] purposes. It was [[drug development|developed]] in the late 1960s and has since been used in [[France]] and several other [[Europe]]an [[countries]], and  although pyrovalerone is still occasionally [[Medical prescription|prescribed]], it is used infrequently due to problems with [[drug abuse|abuse]] and [[drug dependence|dependence]].<ref>{{Cite journal | last1 = Deniker | first1 = P. | last2 = Lôo | first2 = H. | last3 = Cuche | first3 = H. | last4 = Roux | first4 = J. M. | title = Abuse of pyrovalerone by drug addicts | journal = Annales médico-psychologiques | volume = 2 | issue = 4 | pages = 745–748 | year = 1975 | pmid = 9895}}</ref> It is closely related on a [[chemical structure|structural]] level to a number of other stimulants, such as [[MDPV]] and [[prolintane]] (Promotil, Katovit).

 
[[Adverse effect|Side effects]] of pyrovalerone include [[anorexia (symptom)|anorexia]] or [[loss of appetite]], [[anxiety]], fragmented [[sleep]] or [[insomnia]], and [[trembling]], [[Tremor|shaking]], or [[muscle tremor]]s. [[Drug withdrawal|Withdrawal]] following abuse upon [[discontinuation]] often results in [[depression (mood)|depression]].
